- The trend backdrop is active with a 10-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
AAREYDRUGS
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Aarey Drugs & Pharmaceuticals Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
81.47 INR
4.6%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 6.8% above the Trend Line and sits at 62.7% of its 52-week range. The latest completed week returned 4.6%, after a -1.6% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.
Setup score
52
out of 100
Latest Close
81.47 INR
7 Aug 2026
1W Return
4.6%
latest completed week
4W Return
-1.6%
short-term follow-through
12W Return
-8.2%
quarterly tape
Trend Breadth
55.8%
29 of 52 weeks active
Volume Ratio
3.1x
vs 13-week average
- Activity pressure is negative, which weakens the current setup.
- 3 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
4.6%
Latest completed week; four-week move -1.6%.
Indicator stack
65/17
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
6 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 6.8% above the Trend Line and sits at 62.7% of its 52-week range. The latest completed week returned 4.6%, after a -1.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 3.1x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.5912-week average 0.64
12-week confirmation
Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.59Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers
No recent accumulation markers. 3 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -1.6% over four weeks, -8.2% over 12 weeks, and 21.9% over one year. The current trend has remained active for 10 consecutive weeks.
Performance by holding period
Active trend streak10 weeks
Active weeks in one year29
Trend breadth55.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.63Latest activity-pressure read.
Pressure change-271.1%Four-week change in activity pressure.
Leadership6.57Latest relative-leadership reading.
RS change-42.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength29/100Blend of value, momentum, and quality. Underlying universe rank 72; rank 1 is best.
Value37/100Relative valuation strength. Underlying universe rank 64; rank 1 is best.
Quality15/100Profitability and accounting quality. Underlying universe rank 86; rank 1 is best.
Momentum80/100Medium-term price momentum. Underlying universe rank 21; rank 1 is best.
Growth15/100Revenue and earnings growth. Underlying universe rank 86; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework3/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 51.1x Price divided by trailing earnings.
- Price / sales
- 0.5x Market value relative to trailing revenue.
- EV / EBITDA
- 21.1x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -0.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 3.8% Gross profit retained from each unit of revenue.
- Operating margin
- 0.9% Operating profit retained from revenue.
- Free-cash-flow margin
- -0.5% Free cash flow generated from revenue.
- Return on invested capital
- 1.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -0.4% Latest one-year revenue growth.
- EPS growth
- -1.1% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -144.6% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.5% Net share repurchases relative to market value.
- Shareholder yield
- -0.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 3.7x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 6 relevant articles.
0 positive · 5 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-18.5%Distance below the 52-week high.
13-week volatility5.9%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+27.0%Week of 10 Apr.
Worst week-19.3%Week of 27 Mar.
Latest week+4.6%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains5
Flat weeks0
Modest losses6
Sharp losses7
Recent vol5.9%13-week weekly-return volatility.
Base vol8.2%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew6.8% / -5.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank52 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape53/100
Trend, activity pressure, participation, and risk combine to a 53/100 tape read.
Indicator analysis67/100Latest 12-week confirmation: trend 10/12, activity pressure 9/12, relative leadership 11/12.
Activity pressure 0.59; 3 reversal markers Factors37/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Tiny Titans rank 13; Buyback Yield rank 82; Small Cap Core rank 56 SVQF3/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1523.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 6 relevant articles.
Aarey Drugs Allots 25.2 Lakh Shares for ₹12 Crore from Warrants Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 81.47 INR | 4.6% | 76.27 INR | 60.78 INR | -0.63 | 6.57 | 431.4K | On |
| 31 Jul 2026 | 77.86 INR | 0.5% | 75.87 INR | 60.58 INR | -0.51 | 2.99 | 146.7K | On |
| 24 Jul 2026 | 77.50 INR | 3.5% | 75.48 INR | 60.35 INR | -0.21 | 5.48 | 110.7K | On |
| 17 Jul 2026 | 74.90 INR | -9.6% | 75.26 INR | 60.06 INR | 0.13 | -0.05 | 24.7K | On |
| 10 Jul 2026 | 82.83 INR | -2.4% | 75.05 INR | 59.80 INR | 0.37 | 11.42 | 134.2K | On |
| 3 Jul 2026 | 84.87 INR | -8.2% | 74.52 INR | 59.48 INR | 0.32 | 14.29 | 5.9K | On |
| 26 Jun 2026 | 92.50 INR | 10.6% | 74.22 INR | 59.14 INR | 0.22 | 26.19 | 0 | On |
| 19 Jun 2026 | 83.60 INR | 7.4% | 74.06 INR | 58.77 INR | 0.10 | 15.13 | 128.3K | On |
| 12 Jun 2026 | 77.85 INR | 0.0% | 74.36 INR | 58.45 INR | 0.16 | 9.83 | 67.7K | On |
| 5 Jun 2026 | 77.84 INR | -0.2% | 74.96 INR | 58.16 INR | 0.34 | 11.78 | 104.2K | On |
| 29 May 2026 | 77.99 INR | -6.9% | 75.61 INR | 57.86 INR | 0.58 | 11.95 | 63.9K | Off |
| 22 May 2026 | 83.74 INR | -5.6% | 76.18 INR | 57.56 INR | 0.82 | 20.21 | 258.0K | Off |
| 15 May 2026 | 88.70 INR | -3.7% | 76.32 INR | 57.21 INR | 0.96 | 28.87 | 362.4K | Off |
| 8 May 2026 | 92.12 INR | 1.1% | 76.29 INR | 56.82 INR | 0.98 | 32.28 | 612.3K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.